Hung T. Khong

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 626 citations · Full text

Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth

Yuhua Zhao, Ming Zhou, H Liu et al. · Oncogene · 2009 · 279 citations

Breast Oncology, Biochemistry, Medicine +10

Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes From a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC Expression

Hung T. Khong, Qiong J. Wang, Steven A. Rosenberg · Journal of Immunotherapy · 2004 · 207 citations

Class Ii, Antigen Loss, Immunology +20

Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines

Yangbing Zhao, Zhili Zheng, Paul F. Robbins et al. · The Journal of Immunology · 2005 · 195 citations · Full text

Survival, Persistence, and Progressive Differentiation of Adoptively Transferred Tumor-Reactive T Cells Associated with Tumor Regression

Jianping Huang, Hung T. Khong, Mark E. Dudley et al. · Journal of Immunotherapy · 2005 · 190 citations

Tumor Regression, Cell Therapy, T-regulatory Cell +21